Clinical uses of GM-CSF, a critical appraisal and update

Biologics: Targets and Therapy

Volumn 2, Issue 1, 2008, Pages 13-27

  Arellano, Martha ^a   Lonial, Sagar ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Cancer; G CSF; GM CSF; Hematopoietic cytokines

Indexed keywords

EID: 77955538712     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/btt.s1355     Document Type: Review

References (133)

1. Amsen D, Blander JM, Lee GR, et al. 2004. Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-presenting cells. Cell, 117:515-26.
2. Arellano ML, Langston A, Winton E, et al. 2007. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience. Biol Blood Marrow Transplant, 13 116-23.
3. Arpinati M, Green CL, Heimfeld S, et al. 2000. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood, 95:2484-90.
4. Balkwill F, Mantovani A. 2001. Infl ammation and cancer: back to Virchow? Lancet, 357:539-45.
5. Bancereau J, Steinman RM. 1998. Dendritic cells and the control of immunity. Nature, 392:245-52.
6. Banchereau J, Briere F, Caux C, et al. 2000. Immunobiology of dendritic cells. Ann Rev Immunol, 18:767-811.
7. Basak Saroj K, Harui A, Stolina M, et al. 2002. Increased dendritic cell number and function following continuous in vivo infusion of granulocyte macrophage-colony-stimulating factor and interleukin-4. Blood, 99:2869-79.
8. Bendandi M, Gocke CD, Kobrin CB, et al. 1999. Complete molecular remissions induced by patient-specifi c vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med, 5:1171-7.
9. Bensinger WI, Martin PJ, Storer B, et al. 2001. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. [see comments]. N Engl J Med, 344:175-81.
10. Berthier R, Martinon-Ego C, Laharie AM, et al. 2000. A two-step culture method starting with early growth factors permits enhanced production of functional dendritic cells from murine splenocytes. J Immunol Methods, 239:95-107.
11. Borrello I and Pardoll D. 2002. GM-CSF-based cellular vaccines: a review of the clinical experience. Cytokine Growth Factor Rev, 13:185-93.
12. Boyer MW, Waller EK, Bray RA, et al. 2000. Cytokine upregulation of the antigen presenting function of acute myeloid leukemia cells. Leukemia, 14:412-8.
13. Cashen AF, Link D, Devine S, et al. 2004. Cytokines and stem cell mobilization for autologous and allogeneic transplantation. Curr Hematol Rep, 3:406-12.
14. Cassaday RD, Sondel PM, King DM, et al. 2007. A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients. Clin Cancer Res, 13:540-9.
15. Chow KU, Schneider B, Mitrou PS, et al. 2001. Infl uence of various cytokines on the expression of CD20 on the surface of CLL-cells in vitro. Leuk Res, 25:99-100.
16. Coccia EM, Severa M, Giacomini E, et al. 2004. Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol, 34:796-805.
17. Coppin C, Porzsolt F, Awa A, et al. 2005. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev, CD001425.
18. Correale P, Marsili S, Sabatino M, et al. 2005. Immunotherapy of renal cell carcinoma with granulocyte macrophage colony stimulating factor and very low dose interleukin-2. Oncol Rep, 13:751-6.
19. Cortes J, Kantarjian H, O'brien S, et al. 1998. GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia. Leukemia, 12:860-4.
20. Cuenca A, Cheng F, Wang H, et al. 2003. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specifi c t-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res, 63:9007-9015.
21. Cvetkovic RS, Perry CM. 2006. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs, 66:791-820.
22. Davidson JA, Musk AW, Wood BR, et al. 1998. Intralesional cytokine therapy in cancer: a pilot study of GM-CSF infusion in mesothelioma. J Immunother, 21:389-98.
23. De Gast GC, Batchelor D, Kersten MJ, et al. 2003. Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma. British Journal of Cancer, 88:175-80.
24. De Gast GC, Klumpen HJ, Vyth-Dreese FA, et al. 2000. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin Cancer Res, 6:1267-72.
25. Dillon S, Agrawal A, Van Dyke T, et al. 2004. A toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signalregulated kinase mitogen-activated protein kinase and c-Fos in dendritic cells. J Immunol, 172:4733-43.
26. Disis ML, Grabstein KH, Sleath PR, et al. 1999. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res, 5:1289-1297.
27. Dranoff G, Crawford AD, Sadelain M, et al. 1994. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science, 264:713-6.
28. Dranoff G, Jaffee E, Lazenby A, et al. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specifi c, and long-lasting anti-tumor immunity. Proc Natl Acad Sci, USA, 90:3539-43.
29. Eksioglu EA, Mahmood SS, Chang M, et al. 2007. GM-CSF promotes differentiation of human dendritic cells and T lymphocytes toward a predominantly type 1 proinfl ammatory response. Exp Hematol, 35:1163-71.
30. Enzler T, Gillessen S, Manis JP, et al. 2003. Defi ciencies of GM-CSF and interferon gamma link infl ammation and cancer. J Exp Med, 197:1213-9.
31. Fagnoni FF, Oliviero B, Giorgiani G, et al. 2004. Reconstitution dynamics of plasmacytoid and myeloid dendritic cell precursors after allogeneic myeloablative hematopoietic stem cell transplantation. Blood, 104:281-9.
32. Fantuzzi G. 2003. Cytokine Knockouts. New Jersey: Humana Press.
33. Fattorossi A, Battaglia A, Pierelli L, et al. 2001. Effects of granulocytecolony-stimulating factor and granulocyte/macrophage-colonystimulating factor administration on T-cell proliferation and phagocyte cell-surface molecules during hematopoietic reconstitution after autologous peripheral blood progenitor cell transplantation. Cancer Immunol Immunother, 49:641-8.
34. Ferlazzo G, Klein J, Paliard X, et al. 2000. Dendritic cells generated from CD34+ progenitor cells with fl t3 ligand, c-kit ligand, GM-CSF, IL4, and TNF-alpha are functionalantigen-presneting cells resembling monocytederived dendritic cells. Journal of Immunotherapy, 23:48-58.
35. Fonteneau JF, Gilliet M, Larsson M, et al. 2003. Activation of infl uenza virus-specifi c CD4+ and CD8+ T-cells: a new role for plasmacytoid dendritic cells in adaptive immunity. Blood, 101:3520-3526.
36. Gajewski T, Flickinger S. 2000. A Phase II study of outpatient chemoimmunotherapy using cisplatin and DTIC followed by GM-CSF, IL-2, and IFN-alpha-2b in patients with metastatic melanoma. Proc Am Soc Clin Oncol, 19:(abstr 2271).
37. Garcia-Carbonero R, Mayordomo JI, Tornamira MV, et al. 2001. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst, 93:31-38.
38. Gasparetto C, Gasparetto M, Morse M, et al. 2002. Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-ligand and G-CSF or GM-CSF. Cytokine, 18:8-19.
39. Gaudernack G, Gjertsen MK. 1999. Combination of GM-CSF with antitumour vaccine strategies. Eur J Cancer, 35:S33-5.
40. Gazitt Y, Akay C, Thomas C 3rd. 2006. No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-hodgkin's lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF. Stem Cells Dev, 15:269-77.
41. Gibbs P, Oday S, Richards J, et al. 2000. A multicenter phase ii study of modifi ed biochemotherapy (BCT) for stage IV melanoma incorporating temozolomide, decrescendo interleukin-2 (IL-2) and GM-CSF. Proc Am Soc Clin Oncol (abstr 2255), 19.
42. Gilliet M, Liu YJ. 2002. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med, 195:695-704.
43. Groenewegen G, Bloem A, De Gast GC. 2002. Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colonystimulating factor, low-dose interleukin-2, and interferon-alpha. Cancer Immunol Immunother, 51:630-6.
44. Groenewegen G, De Gast GC. 1999. GM-CSF can cause T cell activation; results of sequential chemo-immunotherapy. Eur J Cancer, 35(Suppl 3):S23-4.
45. Grouard G, Rissoan MC, Filgueira L, et al. 1997. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med, 185:1101-11.
46. Hart DN. 1997. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood, 90:3245-87.
47. Hersey P, Menzies SW, Halliday GM, et al. 2004. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol Immunother, 53:125-34.
48. Hersh EM, Stopeck AT. 1997. Advances in the biological therapy and gene therapy of malignant disease. Clin Cancer Res, 3:2623-9.
49. Hoption Cann SA, Van Netten JP, Van Netten C, et al. 2002. Spontaneous regression: a hidden treasure buried in time. Med Hypotheses, 58:115-19.
50. Hotton KM, Khorsand M, Hank JA, et al. 2000. A phase Ib/II trial of granulocyte-macrophage-colony stimulating factor and interleukin-2 for renal cell carcinoma patients with pulmonary metastases: a case of fatal central nervous system thrombosis. Cancer, 88:1892-901.
51. Hsu FJ, Benike C, Fagnoni F, et al. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med, 2:52-8.
52. Hung K, Hayashi R, Lafond-Walker A, et al. 1998. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med, 188:2357-68.
53. Inaba K, Inaba M, Romani N, et al. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med, 176:1693-702.
54. Jaffee EM, Hruban RH, Biedrzycki B, et al. 2001. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol, 19:145-56.
55. Janik JE, Miller LL, Korn EL, et al. 2001. A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma. Blood, 97:1942-6.
56. Kadowaki N, Ho S, Antonenko S, et al. 2001. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med, 194:863-9.
57. Keilholz U, Weber J, Finke JH, et al. 2002. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother, 25:97-138.
58. Kessinger A, Armitage JO, Landmark JD, et al. 1986. Reconstitution of human hematopoietic function with autologous cryopreserved circulating stem cells. Exp Hematol, 14:192-6.
59. Kolb HJ, Rank A, Chen X, et al. 2004. In-vivo generation of leukaemiaderived dendritic cells. Best Pract Res Clin Haematol, 17:439-51.
60. Korbling M, Anderlini P. 2001. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood, 98:2900-8.
61. Korbling M, Burke P, Braine H, et al. 1981. Successful engraftment of blood derived normal hemopoietic stem cells in chronic myelogenous leukemia. Exp Hematol, 9:684-90.
62. Kusumoto M, Umeda S, Ikubo A, et al. 2001. Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene. Cancer Immunol Immunother, 50:373-81.
63. Kuwana M, Kaburaki J, Wright TM, et al. 2001. Induction of antigen-specifi c human CD4(+) T cell anergy by peripheral blood DC2 precursors. Eur J Immunol, 31:2547-57.
64. Larsson M, Fonteneau JF, Bhardwaj N. 2003. Cross-presentation of cellassociated antigens by dendritic cells. Curr Top Microbiol Immunol, 276:261-75.
65. Leong SP, Enders-Zohr P, Zhou YM, et al. 1999. Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma. J Immunother, 22:166-74.
66. Levine AM, Reed JA, Kurak KE, et al. 1999. GM-CSF-defi cient mice are susceptible to pulmonary group B streptococcal infection. J Clin Invest, 103:563-9.
67. Li JM, Waller EK. 2004. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation. Biol Blood Marrow Transplant, 10:540-51.
68. Lieschke GJ, Grail D, Hodgson G, et al. 1994. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell defi ciency, and impaired neutrophil mobilization. Blood, 84:1737-46.
69. Lissoni P, Mengo S, Bucovec R, et al. 2003. Clinical and biological effects of interleukin-2 with or without a concomitant administration of granulocyte-macrophage colony-stimulating factor in metastatic cancer patients. In Vivo, 17:73-5.
70. Lonial S, Hicks M, Rosenthal H, et al. 2004. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colonystimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. Biol Blood Marrow Transplant, 10:848-57.
71. Lonial S, Mcmillan S, Torre C, et al. 2006. A randomized trial to evaluate the impact of cytokines (G-CSF or GM + G-CSF) on dendritic cell and T-cell content and function when mobilizing normal donors for allogeneic progenitor cell transplant. Blood, 108:(abstr 3377).
72. Lutzky J, Blaustein A, Weingrad D, et al. 2003. Phase I/II study of GM-CSF and thalidomide in patients with high-risk malignant melanoma. Proc Am Soc Clin Oncol, 22:(abstr 2916).
73. Masucci G, Ragnhammar P, Wersall P, et al. 1990. Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A). Cancer Immunol Immunother, 31:231-5.
74. Matzinger P. 1994. Tolerance, Danger, and the Extended Family. Ann Rev Immunol, 12:991-1045.
75. Metcalf D. 1998. Cell-cell signalling in the regulation of blood cell formation and function. Immunol Cell Biol, 76:441-7.
76. Metcalf D, Nicola NA. 1995. The hematopoietic colony stimulating factors. New York, NY: Cambridge University Press.
77. Mizutani K, Takeuchi S, Ohashi Y, et al. 2003. Clinical usefulness of macrophage colony-stimulating factor for ovarian cancers: Long-term prognosis after fi ve years. Oncol Rep, 10:127-31.
78. Mohty M, Olive D and Gaugler B. 2002. Leukemic dendritic cells: potential for therapy and insights towards immune escape by leukemic blasts. Leukemia, 16:2197-204.
79. Motzer RJ, Bukowski RM. 2006. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol, 24:5601-8.
80. Nauts HC, Fowler GA, Bogatko FH. 1953. A review of the infl uence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in man; a critical analysis of 30 inoperable cases treated by Coley's mixed toxins, in which diagnosis was confi rmed by microscopic examination selected for special study. Acta Med Scand Suppl, 44:1-103.
81. Nelson WG, Simons JW, Mikhak B, et al. 2000. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother Pharmacol, 46(Suppl):S67-72.
82. Olivieri A, Lucesole M, Capelli D, et al. 2005. A new schedule of CHOP/ rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation. Biol Blood Marrow Transplant, 11:627-36.
83. Olweus J, Bitmansour A, Warnke R, et al. 1997. Dendritic cell ontogeny: a human dendritic cell lineage of myeloid origin. Proc Natl Acad Sci, USA, 94:12551-6.
84. Paine R 3rd, Morris SB, Jin H, et al. 2001. Impaired functional activity of alveolar macrophages from GM-CSF-defi cient mice. Am J Physiol Lung Cell Mol Physiol, 281:L1210-8.
85. Parmiani G, Castelli C, Santinami M, et al. 2007. Melanoma immunology: past, present and future. Curr Opin Oncol, 19:121-7.
86. Perrot I, Blanchard D, Freymond N, et al. 2007. Dendritic cells infi ltrating human non-small cell lung cancer are blocked at immature stage. J Immunol, 178:2763-9.
87. Rapoport AP, Meisenberg B, Sarkodee-Adoo C, et al. 2002. Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy. Bone Marrow Transplant, 29:303-12.
88. Ravaud A, Delaunay M, Chevreau C, et al. 2001. Granulocyte-macrophage colony-stimulating factor alone or with dacarbazine in metastatic melanoma: a randomized phase II trial. Br J Cancer, 85:1467-71.
89. Reddy V, Iturraspe JA, Tzolas AC, et al. 2004. Low dendritic cell count after allogeneic hematopoietic stem cell transplantation predicts relapse, death, and acute graft-versus-host disease. Blood, 103:4330-5.
90. Repetto L, Biganzoli L, Koehne CH, et al. 2003. EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. European Journal of Cancer, 39:2264-72.
91. Ringden O, Labopin M, Gorin NC, et al. 2004. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the acute leukemia working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol, 22:416-23.
92. Rissoan MC, Soumelis V, Kadowaki N, et al. 1999. Reciprocal control of T helper cell and dendritic cell differentiation. Science, 283:1183-6.
93. Rosenberg SA, Zhai Y, Yang JC, et al. 1998. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst, 90:1894-1900.
94. Rowe JM, Andersen JW, Mazza JJ, et al. 1995. A randomized placebocontrolled phase III study of granulocyte-macrophage colonystimulating factor in adult patients (_55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood, 86:457-62.
95. Ryan CW, Vogelzang NJ, Dumas MC, et al. 2000. Granulocyte-macrophagecolony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials. Cancer, 88:1317-24.
96. Salgia R, Lynch T, Skarin A, et al. 2003. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colonystimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol, 21:624-30.
97. Santiago-Schwarz F, Belilos E, Diamond B, et al. 1992. TNF in combination with GM-CSF enhances the differentiation of neonatal cord blood stem cells into dendritic cells and macrophages. J Leukoc Biol, 52:274-81.
98. Santiago-Schwarz F, Coppock DL, Hindenburg AA, et al. 1994. Identifi cation of a malignant counterpart of the monocyte-dendritic cell progenitor in an acute myeloid leukemia. Blood, 84:3054-62.
99. Schachter J, Rakowsky E, Sulkes A, et al. 1998. A sequential four-drug chemotherapy and biotherapy with interferon alpha and GM-CSF-an innovative protocol for the treatment of metastatic melanoma. Cancer Biother Radiopharm, 13:155-64.
100. Schmidinger M, Steger G, Wenzel C, et al. 2001. Sequential administration of interferon-gamma, GM-CSF, and interleukin-2 in patients with metastatic renal cell carcinoma: results of a phase II trial. J Immunother, 24:257-62.
101. Schmidt W, Maass G, Buschle M, et al. 1997. Generation of effective cancer vaccines genetically engineered to secrete cytokines using adenovirusenhanced transferrinfection (AVET). Gene, 190:211-16.
102. Schmitz N, Bacigalupo A, Hasenclever D, et al. 1998. Allogeneic bone marrow transplantation vs fi lgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: fi rst results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation [see comments]. Bone Marrow Transplant, 21:995-1003.
103. Schmitz N, Beksac M, Hasenclever D, et al. 2002. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood, 100:761-7.
104. Schreiber H. 2003. Tumor Immunology. In Paul W (Ed.) Fundamental Immunology. 5th ed. Lippincott, Williams, and Wilkins.
105. Seymour JF, Lieschke GJ, Grail D, et al. 1997. Mice lacking both granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF have impaired reproductive capacity, perturbed neonatal granulopoiesis, lung disease, amyloidosis, and reduced long-term survival. Blood, 90:3037-49.
106. Siegal FP, Kadowaki N, Shodell M, et al. 1999. The nature of the principal type 1 interferon-producing cells in human blood. Science, 284:1835-7.
107. Simons JW, Jaffee EM, Weber CE, et al. 1997. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res, 57:1537-46.
108. Simons JW, Mikhak B, Chang JF, et al. 1999. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res, 59:5160-8.
109. Simons JW, Sacks N. 2006. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol Oncol, 24:419-24.
110. Slavin S, Naparstek E, Nagler A, et al. 1996. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood, 87:2195-204.
111. Slingluff CL Jr, Petroni GR, Yamshchikov GV, et al. 2003. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol, 21:4016-26.
112. Smith li JW, Kurt RA, Baher AG, et al. 2003. Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fi xed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma. J Immunother, 26:130-8.
113. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol, 24:3187-205.
114. Soiffer R, Hodi FS, Haluska F, et al. 2003. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocytemacrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol, 21:3343-50.
115. Soiffer R, Lynch T, Mihm M, et al. 1998. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocytemacrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci, USA, 95:13141-6.
116. Stanley E, Lieschke GJ, Grail D, et al. 1994. Granulocyte/macrophage colony-stimulating factor-defi cient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci, USA, 91:5592-6.
117. Tate J, Olencki T, Finke J, et al. 2001. Phase I trial of simultaneously administered GM-CSF and IL-6 in patients with renal-cell carcinoma: clinical and laboratory effects. Ann Oncol, 12:655-9.
118. Urbini B, Arpinati M, Bonifazi F, et al. 2003. Allogeneic graft CD34(+) cell dose correlates with dendritic cell dose and clinical outcome, but not with dendritic cell reconstitution after transplant. Exp Hematol, 31:959-65.
119. Vaughan MM, Moore J, Riches PG, et al. 2000. GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): a phase I trial in melanoma. Ann Oncol, 11:1183-9.
120. Venugopal P, Sivaraman S, Huang XK, et al. 2000. Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia. Leuk Res, 24:411-5.
121. Vereecque R, Buffenoir G, Preudhomme C, et al. 2000. Gene transfer of GM-CSF, CD80 and CD154 cDNA enhances survival in a murine model of acute leukemia with persistence of a minimal residual disease. Gene Therapy, 7:1312-16.
122. Verra N, De Jong D, Bex A, et al. 2005. Infi ltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy. Eur Urol, 48:527-33.
123. Verra N, Jansen R, Groenewegen G, et al. 2003. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma. Br J Cancer, 88:1346-51.
124. Volpi I, Perruccio K, Tosti A, et al. 2001. Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. Blood, 97:2514-21.
125. Waller EK, Rosenthal H, Jones TW, et al. 2001. Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. Blood, 97:2948-56.
126. Wang HY, Wang RF. 2007. Regulatory T cells and cancer. Current Opinion in Immunology, 19:217-23.
127. Weber RW, O'Day S, Rose M, et al. 2005. Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-{alpha}2b, and recombinant interleukin-2 for the treatment of metastatic melanoma. J Clin Oncol, 23:8992-9000.
128. Westermann J, Reich G, Kopp J, et al. 2001. Granulocyte/macrophagecolony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma:a pilot study. Cancer Immunol Immunother, 49:613-20.
129. Whiteway A, Corbett T, Anderson R, et al. 2003. Expression of costimulatory molecules on acute myeloid leukaemia blasts may effect duration of fi rst remission. Br J Haematol, 120:442-51.
130. Wos E, Olencki T, Tuason L, et al. 1996. Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma. Cancer, 77:1149-53.
131. Yagci M, Akar I, Sucak GT, et al. 2005. GM-CSF does not increase CD20 antigen expression on chronic lymphocytic leukemia lymphocytes. Leuk Res, 29:735-8.
132. Zhan Y, Lieschke GJ, Grail D, et al. 1998. Essential roles for granulocytemacrophage colony-stimulating factor (GM-CSF) and G-CSF in the sustained hematopoietic response of Listeria monocytogenes-infected mice. Blood, 91:863-9.
133. Zittoun R, Suciu S, Mandelli F, et al. 1996. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia:a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol, 14:2150-9.